Israeli Coronavirus Treatment Shows 100% Survival Rate In Early Trials
Early trials of a coronavirus treatment developed by Israeli company Pluristem Therapeutics Inc.’s is showing signs of hope as the world battles with the virus.
Seven patients placed on ventilators in hospital Intensive Care Units were tested in the trial and all seven survived as a result of the treatment, according to a company press release.
“We are pleased with this initial outcome of the compassionate use program, and committed to harnessing PLX cells for the benefit of patients and healthcare systems. In order to maximize PLX cells’ impact on patient recovery and to work towards making our treatment widely available, we plan to quickly move forward into a clinical development program,” Pluristem CEO and President, Yaky Yanay said in a statement.
“Pluristem is dedicated to using its competitive advantages in large-scale manufacturing to potentially deliver PLX cells to a large number of patients in significant need. We believe that research and governmental funding may be available to Pluristem to support the use of PLX cells for patients suffering from COVID19 and are targeting such funding,”
According to the release, Pluristem is hoping to open the treatment to worldwide clinical trials.